GAIL WAKEFIELD

Mode of Suppression of Pituitary and Gonadal Function After Acute or Prolonged Administration of a Luteinizing Hormone-Releasing Hormone Antagonist in Normal Men*

SPYROS N. PAVLOU, GAIL WAKEFIELD, Nicole Schlechter et al. · The Journal of Clinical Endocrinology & Metabolism · 1989 · 74 citations

Suppression of Pituitary-Gonadal Function by a Potent New Luteinizing Hormone-Releasing Hormone Antagonist in Normal Men*

SPYROS N. PAVLOU, GAIL WAKEFIELD, Donald P. Island et al. · The Journal of Clinical Endocrinology & Metabolism · 1987 · 66 citations

Gynecology, Pharmacotherapy, Reproductive Biology +18

Single Subcutaneous Doses of a Luteinizing Hormone-Releasing Hormone Antagonist Suppress Serum Gonadotropin and Testosterone Levels in Normal Men*

SPYROS N. PAVLOU, ROWAN C. DEBOLD, Donald P. Island et al. · The Journal of Clinical Endocrinology & Metabolism · 1986 · 58 citations

Phase I study of the antineovascularization drug CM101.

Russell F. DeVore, Carl G. Hellerqvist, GAIL WAKEFIELD et al. · PubMed · 1997 · 41 citations

Bacterial Polysaccharide, Immunology, Pathology +18

Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial

Barbara D. Wamil, Gary B. Thurman, Håkan Sundell et al. · Journal of Cancer Research and Clinical Oncology · 1997 · 29 citations · Full text

Soluble E-selectin, Tumor-inhibiting Anti-neovascularization Agent, Medicine +9